GCT3013-01 (#1216)
Laufzeit: 01.01.2020 - 31.12.2040
imported
Kurzfassung
A phase 1/2, open-label, dose-escalation trial of GEN3013 in patients with relapsed, progressive or refractory B-Cell Lymphoma
Laufzeit: 01.01.2020 - 31.12.2040
A phase 1/2, open-label, dose-escalation trial of GEN3013 in patients with relapsed, progressive or refractory B-Cell Lymphoma